Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,616 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohort A: placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants

NCT05877053
View directory record Official record
Conditions
Healthy Participants
Interventions
CK-4021586, Placebo for CK-4021586
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

NCT03715829
View directory record Official record
Conditions
Active Non-segmental Vitiligo
Interventions
PF-06651600, placebo, PF06700841, narrow-band UVB phototherapy
Drug · Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
40
States / cities
Huntington Beach, California • Irvine, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 2 Interventional

Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)

NCT00993707
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
CTX-100 (formerly ETX-100) (hyaluronic acid)
Drug
Lead sponsor
Turino, Gerard, M.D.
Individual
Eligibility
40 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Tucson, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 15, 2026, 2:39 PM EDT
Terminated Phase 2 Interventional

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

NCT01624636
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Placebo, LFG316
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Phoenix, Arizona • Winter Haven, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 15, 2026, 2:39 PM EDT
Terminated Phase 1 Interventional

A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)

NCT04948554
View directory record Official record
Conditions
Systemic Sclerosis With and Without Interstitial Lung Disease
Interventions
MK-2225, Placebo
Biological
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults

NCT06469151
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5148, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Anniston, Alabama • Glendale, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

NCT05762471
View directory record Official record
Conditions
Overweight or Obesity, Type2 Diabetes Mellitus
Interventions
GSBR-1290, Placebo
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Anaheim, California • Chula Vista, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects

NCT01030224
View directory record Official record
Conditions
Healthy
Interventions
AZD9742, Placebo to match AZD9742
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
23 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2012 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

FTIH of ECC4703 in Healthy Volunteers

NCT05552274
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
ECC4703, Placebo
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 15, 2026, 2:39 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

NANOVAE to Treat Knee Osteoarthritis (KOA)

NCT06606561
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF), 0.9% Sodium Chloride Injection, USP
Drug
Lead sponsor
Nova Vita Laboratory
Industry
Eligibility
21 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects

NCT02125435
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics of ASP2408
Interventions
ASP2408, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 15, 2026, 2:39 PM EDT
Suspended Phase 1Phase 2 Interventional

Vitamin D and Bone Homeostasis in Ortho Polytrauma Patients

NCT03066817
View directory record Official record
Conditions
Vitamin D Deficiency, Polytrauma, Orthopedic Disorder
Interventions
Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL], Propylene Glycol
Drug
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 15, 2026, 2:39 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis

NCT04004325
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Overweight or Obesity
Interventions
FT-4101, FT-4101 placebo, Deuterated Water
Drug · Other
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Chula Vista, California • Montclair, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 15, 2026, 2:39 PM EDT
Terminated Phase 1 Interventional

Study of REGN1193 in Patients With Type 2 Diabetes Mellitus

NCT02284425
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
REGN1193, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
25 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Atlanta, Georgia • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 15, 2026, 2:39 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

First in Human Phase 1 Ascending Dose Study of PanChol in Healthy Volunteers

NCT05657782
View directory record Official record
Conditions
Cholera, Cholera Vaccine Toxicity
Interventions
PanChol
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)

NCT05645757
View directory record Official record
Conditions
Bacterial Infection
Interventions
Ertapenem, Placebo, WCK 6777, Zidebactam
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

NCT05891236
View directory record Official record
Conditions
Malaria
Interventions
MAM01 1.5 mg/kg, Placebo, MAM01 5 mg/kg, MAM01 10 mg/kg, MAM01 40 mg/kg, MAM01 450 mg, Control, MAM01 600 mg, MAM01 900 mg
Biological · Other
Lead sponsor
Gates Medical Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 15, 2026, 2:39 PM EDT
Withdrawn Phase 3 Interventional

Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric

NCT03602781
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, iNO
Drug
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 15, 2026, 2:39 PM EDT
Recruiting Phase 2 Interventional

A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

NCT07227636
View directory record Official record
Conditions
Colorectal Cancer, Rectal Cancer
Interventions
Botensilimab, Balstilimab, Placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 15, 2026, 2:39 PM EDT
Terminated Phase 2 Interventional

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain

NCT05359133
View directory record Official record
Conditions
Chemotherapy-induced Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Interventions
Tetrodotoxin, Placebo
Drug
Lead sponsor
Wex Pharmaceuticals Inc.
Industry
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Santa Ana, California • Santa Rosa, California • Port Charlotte, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of CTS21166 to Treat Alzheimer Disease

NCT00621010
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CTS21166 (ZPQ-21166)
Drug
Lead sponsor
CoMentis
Industry
Eligibility
22 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 9, 2008 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

NCT05251259
View directory record Official record
Conditions
Asthma
Interventions
Atuliflapon, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
64
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 1 Interventional

OTO-104 for Meniere's Disease

NCT01084525
View directory record Official record
Conditions
Meniere's Disease
Interventions
OTO-104 (steroid) 3 mg, Placebo, OTO-104 (steroid) 12 mg
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 2 Interventional

Study of NNZ-2566 in Patients With Traumatic Brain Injury

NCT00805818
View directory record Official record
Conditions
Brain Injuries
Interventions
NNZ-2566, Placebo
Drug
Lead sponsor
Neuren Pharmaceuticals Limited
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
20
States / cities
Mobile, Alabama • Tucson, Arizona • Colton, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 15, 2026, 2:39 PM EDT